Osteocyte RANKL: new insights into the control of bone remodeling - PubMed (original) (raw)
Review
Osteocyte RANKL: new insights into the control of bone remodeling
Jinhu Xiong et al. J Bone Miner Res. 2012 Mar.
Abstract
The idea that osteoblasts, or their progenitors, support osteoclast formation by expressing the cytokine receptor activator of NFkB ligand (RANKL) is a widely held tenet of skeletal biology. Two recent studies provide evidence that osteocytes, and not osteoblasts or their progenitors, are the major source of RANKL driving osteoclast formation in cancellous bone. The goal of this review is to highlight the results of these new studies and discuss their implications for our understanding of bone remodeling.
Copyright © 2012 American Society for Bone and Mineral Research.
Figures
Figure 1
Model depicting mechanisms by which osteocytes may independently control bone resorption and bone formation. Osteoclasts (OCs) and osteoblasts (OBs) within a cancellous BMU are shown as being derived from precursors (pOC and pOB). Osteocytes alter the rate of bone remodeling by controlling osteoclast formation via production of RANKL. On the other hand, osteocytes also control the balance between formation and resorption by regulating osteoblast formation via production of sclerostin. Sclerostin may have additional actions such as stimulation of RANKL expression by osteocytes.
References
- Gowen LC, Petersen DN, Mansolf AL, Qi H, Stock JL, Tkalcevic GT, Simmons HA, Crawford DT, Chidsey-Frink KL, Ke HZ, McNeish JD, Brown TA. Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. J Biol Chem. 2003;278:1998–2007. - PubMed
- Brunkow ME, Gardner JC, Van NJ, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, Sabo PJ, Fu Y, Alisch RS, Gillett L, Colbert T, Tacconi P, Galas D, Hamersma H, Beighton P, Mulligan J. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001;68:577–589. - PMC - PubMed
- Balemans W, Ebeling M, Patel N, Van HE, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den EJ, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van HW. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST) Hum Mol Genet. 2001;10:537–543. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- AG13918/AG/NIA NIH HHS/United States
- AR049794/AR/NIAMS NIH HHS/United States
- P01 AG013918/AG/NIA NIH HHS/United States
- I01 BX000294/BX/BLRD VA/United States
- 1UL1RR029884/RR/NCRR NIH HHS/United States
- R01 AR049794-09/AR/NIAMS NIH HHS/United States
- R01 AR049794/AR/NIAMS NIH HHS/United States
- UL1 RR029884/RR/NCRR NIH HHS/United States